Stifel analyst Andrew Partheniou lowered the firm’s price target on Trulieve Cannabis to C$8 from C$20 and keeps a Buy rating on the shares. The firm is reducing its broader core MSO market estimates by 9% in 2024 and modifying its valuation methodology for U.S. cannabis producers for “low growth.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TCNNF:
- Rising High: Exclusive talk with biotech company Tryp Therapeutics
- Trulieve Cannabis appoints Ryan Blust as interim CFO
- Rising High: Exclusive talk with biotech company Enveric Biosciences
- CytoSorbents appoints D’Amico as Chief Financial Officer
- Rising High: Exclusive talk with mental healthcare company Numinus
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue